LMB763



NAME OF DRUG : LMB763

ALSO KNOWN AS : LMB763

LABORATORY : NOVARTIS

STATUS AND ADVANCEMENT

Type of drug : non-BA FXR agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated time to market : 94 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON LMB763

SOME PUBLICATIONS RELATED WITH LMB763

December 2017 : Targeting bile acids and lipotoxicity for NASH treatment

July 2017 : Fibroblast growth factor 19, a double-edged sword

January 2017 : Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15 (necessity to monitor HCC risk with FXR agonists )

February 2013 : Dual actions of fibroblast growth factor 19 on lipid metabolism

February 2012 : Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

January 2012 : FGF19 and Cancer

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH LMB763


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE